Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.

23 Jul 2010

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has entered into a debt for equity exchange agreement with its chairman and CEO Michael T. Flavin, Ph.D.

23 Jul 2010

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

Vermillion, Inc., a molecular diagnostics company, today announced that it is relocating its corporate headquarters from Fremont, California to Austin, Texas. Vermillion has executed a two-year lease for a new principal place of business at 12117 Bee Cave Road, Building Two, Suite 100, Austin, TX 78731. Vermillion will continue to operate research and development, regulatory and quality operations in California. All other functions will be conducted at the Austin offices.

23 Jul 2010

NVCI, CSN and Workforce CONNECTIONS partner to launch ARRA funded nursing internship program

Nevada Cancer Institute (NVCI) is launching its Plus One Program, a paid nursing internship initiative to equip nursing graduates with advanced training to give them an edge in today's competitive nursing job market. After completing a paid one-year internship at NVCI, participants will become oncology nurses, a highly sought-after specialty. These specialized jobs have the potential to pay increased wages, provide excellent benefits and support articulated career ladders within the field of oncology.

23 Jul 2010

New technique to detect abnormal cell circulation in non-small lung cancer

Researchers at The University of Texas M. D. Anderson Cancer Center are testing a new technique for identifying circulating genetically abnormal cells, which can lead to poor prognosis, in patients with non-small cell lung cancer.

23 Jul 2010

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene.

23 Jul 2010

Human Genome Sciences second-quarter revenues increase to $38.8 million

Human Genome Sciences, Inc. today announced financial results for the quarter ended June 30, 2010, and provided highlights of recent key developments.

23 Jul 2010

2010 Life Beyond Cancer Retreat invites applications

The Life Beyond Cancer Foundation is calling for applications from cancer survivors, oncology nurses, social workers, oncologists, and primary care physicians who help diagnose cancer to attend the 2010 Life Beyond Cancer Retreat. The 11th annual retreat, held Nov. 18 – 21 at Lakeway Resort & Spa in Austin, Texas, helps women rekindle their spirits, relax their minds and bodies, and rejuvenate their souls.

23 Jul 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.

22 Jul 2010

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.

22 Jul 2010

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2010.

22 Jul 2010

Researchers develop laser-induced thermal therapy to treat cancer

A group of researchers from Wake Forest University Baptist Medical Center is developing a way to treat cancer by using lasers to light up tiny nanoparticles and destroy tumors with the ensuing heat. Today at the 52nd Annual Meeting of the American Association of Physicists in Medicine in Philadelphia, they will describe the latest development for this technology: iron-containing Multi-Walled Carbon Nanotubes threads of hollow carbon that are 10 thousand times thinner than a human hair.

22 Jul 2010

AstraZeneca provides medicines to patients at Grace Hill Neighborhood Health Centers

AstraZeneca announced today that it is providing medicines at no cost to qualifying patients at Grace Hill Neighborhood Health Centers, Inc. in St. Louis.

22 Jul 2010

Affymetrix launches QuantiGene ViewRNA Assay formats

Affymetrix, Inc. today announced the launch of QuantiGene® ViewRNA Assay formats, which enable a new era of "in situ multiplex gene expression analysis" by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

22 Jul 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.

22 Jul 2010

BSD provides additional information to FDA for 510(k) submission of MicroThermX Microwave Ablation System

BSD Medical Corporation today announced that it has provided the additional information requested by the U.S. Food and Drug Administration (FDA) for review of the 510(k) submission the Company filed for premarket clearance of the Company's Phase II MicroThermX® Microwave Ablation System (MTX-180) for ablation of soft tissue.

22 Jul 2010

CFAR receives a five-year renewal grant to continue AIDS research

The Case Western Reserve University/University Hospitals Case Medical Center Center for AIDS Research announced today it has received a five-year renewal grant from the National Institutes of Health for $9 million. The CFAR provides clinical and technological support to researchers working on HIV-related projects at Case Western Reserve, University Hospital Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, and several international sites.

22 Jul 2010

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

According to a Food and Drug Administration (FDA) advisory committee’s (The Oncology Drugs Advisory Committee, or ODAC) recommendation this Tuesday, the marketing approval of the popular breast cancer drug, Avastin or Bevacizumab should be withdrawn.

21 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Oncology News and Research

Further Reading

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

NVCI, CSN and Workforce CONNECTIONS partner to launch ARRA funded nursing internship program

New technique to detect abnormal cell circulation in non-small lung cancer

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Human Genome Sciences second-quarter revenues increase to $38.8 million

2010 Life Beyond Cancer Retreat invites applications

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Researchers develop laser-induced thermal therapy to treat cancer

AstraZeneca provides medicines to patients at Grace Hill Neighborhood Health Centers

Affymetrix launches QuantiGene ViewRNA Assay formats

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

BSD provides additional information to FDA for 510(k) submission of MicroThermX Microwave Ablation System

CFAR receives a five-year renewal grant to continue AIDS research

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

Genzyme second-quarter revenue decreases to $1.08 billion

Researchers find that increase in leptin may promote colorectal neoplasms

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News